Questions of adhesion, including dosage, route of administration and tolerability, impacted in the evaluations for restriction of use of intramuscular interferon beta, expansion of use of dolutegravir, darunavir and raltegravir, and exclusion of the medicaments fosamprenavir, didanosine, telaprevir and boceprevir from SUS list and exclusion of indications for the use of injectable interferon alfa-2b in the treatment of hepatitis B. This evidence concerns the gene IFNB1 and hepatitis B virus infection.